TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

7 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Type 2 diabetesHeart / cardiovascular disease

    Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes

    Testing how drinking ketone drinks affects heart function in people with type 2 diabetes and heart

    📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF). Plasma ketones are avidly extracted by cardiac muscle and their uptake is not dependent upon insulin or influenced by insulin resistance.

    ✓ Study care freeEarly Phase 1Ages 18–80Learn more →
  • Asthma

    Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation

    Testing early IV magnesium sulfate for people with a moderate asthma flare

    📍 Oklahoma Children's Hospital · Oklahoma City, OK · Get directions →

    This study aims to identify whether early administration of magnesium sulfate in moderate asthma exacerbations can potentially avoid admission, decrease length of stay in the emergency department (ED), decrease length of stay (LOS) in the general hospital floor vs pediatric intensive care unit (PICU), and decrease the need for respiratory support.

    ✓ Study care freeEarly Phase 1Ages 5–17Learn more →
  • Multiple sclerosis (MS)

    Entire-body PET Scans for Multiple Sclerosis

    Testing whether whole-body PET scans can better track MS brain and nerve damage

    📍 Brain Health Alliance · Ladera Ranch, CA · Get directions →

    To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.

    ✓ Study care freeEarly Phase 1Ages 25–55Learn more →
  • Lupus (SLE)

    Safety and Efficacy of ONT01 in Lupus

    Studying whether ONT01 is safe and tolerated in people with lupus

    📍 Hospital for Special Surgery · New York, NY · Get directions →

    ONT01 is a drug that is being studied for the treatment of Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) and is not approved by the FDA. The purpose of this study is to better determine whether ONT01 is safe and tolerated by people with lupus nephritis or SLE.

    ✓ Study care freeEarly Phase 1Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Effects of Ublituximab on Motor Functions in Multiple Sclerosis

    Testing whether ublituximab changes walking and fall risk in people with relapsing multiple

    📍 Georgia State University · Atlanta, GA · +1 more US site · Get directions →

    The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-week ublituximab treatment.

    ✓ Study care freeEarly Phase 1Ages 18–55Learn more →
  • Obesity / overweightHeart / cardiovascular diseaseHigh cholesterol

    Akkermansia Muciniphilia and Metabolic Side Effects of ADT

    Testing how Akkermansia gut bacteria relate to body and blood lipid changes in people with obesity

    📍 London Health Sciences Centre - Victoria Hospital · London, Ontario · Get directions →

    The overriding objectives of this study are: 1. Primary outcomes: 1.

    ✓ Study care freeEarly Phase 1Ages 18+MenLearn more →
  • Multiple sclerosis (MS)

    Assessment of Synaptic Density in MS

    Testing brain imaging to measure synapse density in progressive MS

    📍 Brigham and Women's Hospital · Boston, MA · Get directions →

    The investigators propose to use the novel SV2a-PET ligand, \[F-18\]SDM-8 to assess synaptic density in progressive multiple sclerosis (PMS) (including primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS)), given its improved imaging characteristics and potential for large scale applicability. The specific aims of the study are: Aim 1: To compare the cortical and subcortical grey matter synaptic density in PMS patients, patients with relapsing-remitting MS (RRMS), and healthy subjects, using a novel \[F-18\] labeled synaptic density PET ligand, \[F-18\]SDM8, also known as \[F-18\]SynvesT-1.

    ✓ Study care freeEarly Phase 1Ages 18–60Learn more →